Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01787331 · ClinicalTrials.gov registry record · Phase 2
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01787331 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 21 participants.
The verdict
NCT01787331, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Itraconazole
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-10-29 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01787331
The ClinicalTrials.gov registry entry for NCT01787331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01787331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01787331 about?
NCT01787331 is a clinical study titled "Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer". This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01787331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2013-10-29. Estimated completion is 2018-09-30.
What interventions are being tested in trial NCT01787331?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Itraconazole (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01787331?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.